Holen Sie sich die Stockscreener-App
542.36
1.94%
-11.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$553.58
Offen:
$548.06
24-Stunden-Volumen:
11,405
Relative Volume:
0.02
Marktkapitalisierung:
$42.78B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
39.91
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
+4.71%
1M Leistung:
-5.06%
6M Leistung:
-19.70%
1J Leistung:
+7.04%
1-Tages-Spanne:
$542.26
$548.17
1-Wochen-Bereich:
$527.12
$561.28
52-Wochen-Spanne:
$496.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
542.29 | 43.67B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
447.00 | 167.89B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
169.50 | 121.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
WAT
Waters Corp
|
337.58 | 33.51B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.44 | 32.15B | 7.07B | 1.29B | 993.00M | 4.5355 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Insider sale notice: IDEXX Labs (NASDAQ: IDXX) files Form 144 - Stock Titan
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX announces UK availability of cancer Dx panel for early detection of canine lymphoma - MSN
IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat, guidance hike and new kidney test in - AD HOC NEWS
IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat and updated guidance keep veterinary - AD HOC NEWS
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles - Business Wire
IDEXX Laboratories Inc (IDXX) Stock Up 3.2% and Still Undervalued -- GF Score: 99/100 - GuruFocus
IDEXX Laboratories stock (US45168D1046): fresh Q1 2026 earnings and guidance put diagnostics special - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a 34% Potential Upside for Investors - DirectorsTalk Interviews
Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. $IDXX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Idexx Laboratories Shareholders Approve Governance and Meeting Reforms - The Globe and Mail
IDEXX Laboratories stock (US45167R1041): Diagnostics demand keeps investors focused - AD HOC NEWS
IDXX Technical Analysis & Stock Price Forecast - Intellectia AI
Northwestern Mutual Wealth Management Co. Increases Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories stock (US45168D1046): Q1 2025 earnings highlight growth in pet diagnostics - AD HOC NEWS
IDEXX (NASDAQ: IDXX) declassifies board, grants 25% special-meeting right - Stock Titan
Capitalizing On Growth Prospects, Irene Chang Britt Acquires IDEXX Laboratories Stock Options Worth $771 - Benzinga
Bruce L Claflin Backs Up Beliefs With A Notable Acquisition Of IDEXX Laboratories Stock Options Worth $77 - Benzinga
In A Strategic Move, Joseph L Hooley Acquires IDEXX Laboratories Stock Options Worth $771: Enhancing Valu - Benzinga
Karen Peacock At IDEXX Laboratories Exercises Options Worth $0 - Benzinga
Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0 - Benzinga
Bessemer Group Inc. Trims Stock Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
AustralianSuper Pty Ltd Grows Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day - 01net
IDEXX (IDXX) director Vandebroek receives RSU and option grants as compensation - Stock Titan
Director Sam Samad (NASDAQ: IDXX) receives new stock units and options grant - Stock Titan
IDEXX (IDXX) director granted stock options and deferred stock units - Stock Titan
IDEXX (IDXX) director Lawrence Kingsley awarded RSUs and stock options - Stock Titan
IDEXX (IDXX) grants director RSUs and stock options at $533.92 - Stock Titan
IDEXX (NASDAQ: IDXX) director Hooley granted deferred units and options - Stock Titan
IDEXX (IDXX) director Stuart Essig granted RSUs and options in new equity awards - Stock Titan
IDEXX (NASDAQ: IDXX) director Bruce Claflin granted deferred stock units and options - Stock Titan
IDEXX (IDXX) director receives new stock options and deferred units - Stock Titan
Do You Believe in the Long-Term Growth Potential of IDEXX Laboratories (IDXX)? - Insider Monkey
IDEXX Laboratories stock (US45167R1041): Q1 earnings beat with 14.3% revenue growth - AD HOC NEWS
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $714.36, Implies 35% Upside - TradingView
HARVEY INVESTMENT CO LLC's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
TCW Concentrated Large Cap Growth Fund's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDXX Technical Analysis | Trend, Signals & Chart Patterns | IDEXX LABORATORIES INC (NASDAQ:IDXX) - ChartMill
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $721.5, Implies 35% Upside - TradingView
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 98/100 - GuruFocus
IDEXX Laboratories stock (US45167R1041): Shares fall 5% despite beating earnings estimates - AD HOC NEWS
NewEdge Wealth LLC Acquires 3,629 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc (IDXX) Shares Fall 5.0% -- What GF Score of 99 Tells Investors - GuruFocus
IDEXX Laboratories Drops 5.8% Amid Sector-Wide Selling - AlphaStreet
IDEXX (IDXX) director’s RSUs vest into 257 shares, holdings updated - Stock Titan
IDEXX (IDXX) director Szostak adds 257 shares as RSUs vest into stock - Stock Titan
IDEXX (IDXX) director Karen Peacock converts 101 RSUs into 102-share holding - Stock Titan
Director at IDEXX Laboratories (IDXX) gains 339 shares from RSU vesting - Stock Titan
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.42%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):